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Abstract Levels of mucin-like carcinoma-associated 
antigen (MCA), CA15.3 and carcinoembryonic antigen 
(CEA) were measured in consecutive serum samples of 
40 women with metastatic breast cancer. A change in 
antigen level of more than 25%, either an increase or 
a decrease, was considered to predict progressive or 
responsive disease respectively. A change of less than 
25% was considered to predict stable disease. MCA, 
CA15.3 and CEA were elevated in the serum of 68%, 
76% and 48% of the patients respectively (P < 0.05). 
The overall prediction of clinical course was similar for 
all three markers. A more than 25% increase of MCA, 
CA15.3, and CEA was observed in 61%, 54% and 36% 
respectively. The predictive value of a more than 25% 
increase was high for all three markers: 94%, 94%, 
83%. Changes in marker levels were correlated with 
each other. Logistic regression analysis showed that 
combining MCA and CA15.3 did not improve the 
prediction further. In conclusion, these tumour 
markers may help in evaluating the disease course and 
there is no advantage in combining MCA and 
CA15.3. 
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Introduction 
Carcinoembryonic antigen (CEA) is a widely used tu- 
rnout marker in monitoring patients with advanced 
metastatic breast cancer (Beard and Haskell 1986; Bi- 
eglmayer et al. 1989). Changes in elevated CEA levels 
correlate with changes in disease activity in 33%-85% 
of patients, the higher percentages having cut-off levels 
above 20 ng/ml (Beard and Haskell 1986; Colomer et 
al. 1989; Loprinzi et al. 1986; Haagensen et al. 1978; 
Tormey and Waalkes 1978; Waalkes et al. 1984). How- 
ever, its use is limited by low sensitivity. Elevated levels 
vary from 35% to 70% in different series (Bieglmayer et 
al. 1989; Haagensen et al. 1978; Tormey and Waalkes 
1978; Waalkes et al. 1984). Routine use of the CEA 
assay has been discouraged with the contention that it 
does not lead to more effective treatment (Fletcher 
1986). Recently two new immunoassays for breast can- 
cer have been developed using CA15.3 and mucin-like 
carcinoma-associated antigen (MCA) (Bieglmayer et al. 
1989; Hayes et al. 1986). The incidence of elevated 
CA15.3 levels in patients with metastatic breast cancer 
has been reported to be as high as 80% and therefore 
this marker may be of value in monitoring the clinical 
course (Hayes et al. 1986). Correlation with clinical 
course was found to vary from 60% to 75% (Pons- 
Anicet et al. 1987; Tondini et al. 1988). 
MCA has also been reported to be a sensitive marker 
for breast carcinoma. Sensitivity and specificity appear 
comparable with those of CA15.3 (Bieglmayer et al. 
1989; Linsley et al. 1988; St/ihli et al. 1988; de Wit et al. 
1991; Miserez et al. 1991). In order to determine 
whether these two newly developed markers are more 
suitable for monitoring, we examined CEA, MCA and 
CA15.3 levels in the serum of patients with advanced 
breast cancer and related changes to the clinical course. 
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Materials and methods 
Sample collection 
Serum samples of a consecutive series of patients with metastatic 
breast cancer were collected. These samples were drawn at the time 
of clinical tumour evaluation. Appropriate marker values were only 
considered if sufficient data on treatment response during that 
period and follow-up were available. Evaluable patients were de- 
fined as having measurable or evaluable metastatic disease and 
a minimum of two serum samples with an interval of at least 
1 month. 
Statistical analysis 
The x<test was used to compare the percentages of elevations of the 
three markers. The Wilcoxon test was used to explore the relation 
between the first and second value of each marker. The Spearman 
test was used to examine the correlation between course of disease 
(response, progressive disease, stable disease) and the difference in 
marker level, which was classified as t for a 25% decrease, 2 for a less 
than 25% decrease or increase and 3 for a more than 25% increase 
of the initial marker level. The Spearman test was also used to 
examine the correlation between the differences in the different 
markers. Logistic regression analysis was used to test the efficacy of 
the three tests. 
Criteria of evaluation 
Measurement of disease course (response, progression, or stable 
disease) was determined by clinical examination, plain radiographs, 
computer-aided tomography, ultrasonography, and bone scans. 
A response required a more than 50% decrease in size of measurable 
or evaluable lesions, whilst disease progression required an increase 
of 25 % or the appearance ofnew lesions. Stable disease was defined 
as neither esponse nor progression of disease. Pleural effusions and 
changes in liver function tests were not by themselves considered 
evaluable criteria. In the presence of osseous metastases a the only 
available disease parameter, progression required the appearance of
new lesions on serial bone scans or new osteolytic lesions on radio- 
graphs, whereas a response required both the disappearance or
decrease of isotope uptake on a bone scan combined with at least 
some other evidence such as a decline in serum alkaline phosphate, 
recalcification of osteolytic lesions and improvement of the patient 
performance status. 
Determination of tumour marker levels 
Enzyme immunoassays were used to determine MCA (Hoffman-la 
Roche, Basel; Switzerland), CA15.3 (CIS, Gif sur Yvette-Cedex, 
France) and CEA (Abbot, Amstelveen, The Netherlands) levels. 
Values above the 99th percentile of the normal value distribution 
were considered elevated: MCA 16 U/ml, CA15.3 30 U/ml and CEA 
5 ng/ml. All samples were measured twice. 
Analysis of Results 
Changes of more than 25 % from the initial marker serum concentra- 
tions were arbitrarily defined as significant. To avoid multiple- 
measurement bias by repetitive measurements in cases of concord- 
ant observations, only the first two blood samples were used for the 
analysis. Sensitivity and specificity and positive predictivue values of 
changes in serum concentrations were calculated. The clinical course 
was divided into progressive or non-progressive disease, the latter 
comprising both responsive and stable disease. To qualify for the 
category of non-progressive disease during the observation period, it 
was required that this condition was maintained for at least 
3 months after the second measurement. This excluded the possib- 
ility that marker changes were indicative of disease progression 
before this was clinically detectable. Sensitivity was defined as the 
proportion of the people with progressive disease and an increase of 
their marker level of more than 25%. Specificity was defined as the 
proportion of the people with non-progressive disease and a marker 
level increase less than 25%. Predictive value was defined as the 
proportion of patients with a more than 25% increase who had 
progressive disease, 
Results 
Patient characteristics 
A consecutive series of 76 patients with metastatic 
breast cancer was examined; 40 patients had both 
measurable or evaluable disease, and two appropriate 
serum samples. Nineteen patients were excluded be- 
cause only one serum sample was available, and 17 
patients had no measurable orevaluable disease. Of the 
40 patients who were included in the analysis, the mean 
age was 63.9 + 13.4 years. Twenty-seven patients re- 
ceived hormonal treatment, 8 patients received chemo- 
therapy and 5 patients received no antitumour therapy. 
At the time of the second serum sample 28 patients were 
deemed to have progressive disease and 12 patients had 
non-progressive disease, of whom 5 applied for objec- 
tive tumour egression, and 7 had stable disease. 
Nineteen patients had bone metastases predomi- 
nantly, 12 patients had visceral metastases, and 9 pa- 
tients had both extensive bone and visceral metastases; 
65% of all patients had two or more metastatic sites. 
The mean interval between follow-up samples was 
4.5 _+ 3.4 months. 
Comparison of circulating MCA, CA15.3 
and CEA levels 
MCA and CA15.3 were elevated in the serum of 67.5% 
and 75.6% of patients respectively, whereas CEA was 
elevated in 47.5% of patients. This difference was stat- 
istically significant (overall Z2= 7.04, P < 0.05; CEA 
versus MCA Z 2= 3.2, P = 0.1; CEA versus CA 15.3 
X 2 = 6.4, P = 0.05). In 16 cases (40%) all three markers 
were elevated, in 15 cases MCA and CA15.3 were 
positive whereas CEA was negative (37.5%) and in 
7 cases (17.5%) only one marker was elevated. 
Table 1 shows the data on sensitivity, specificity and 
positive predictive values. The sensitivity of a more than 
25% increase of MCA, CA15.3 and CEA was 60.7%, 
53.6% and 35.7% respectively (Za = 3.7, P = 0.1), The 
predictive value of a more than 25% increase was high 
(but not statistically different) for all three markers 
(94.4%, 93.8% and 83.3% respectively). 
Table 1 Sensitivity, specificity 
and positive predictive alues of 
more than 25% changes in
serum marker levels 
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Evaluation MCA CA15.3 CEA 
Sensitivity 60.7% (17/28) 53.6 (15/28) 35.7 (10/28))~2 = 6.6 P < 0.05 
Specificity 91.7% (11/12) 90.0 (9/10) 83.3 (10/12))~2 = 0.44 NS 
Positive predictive value 94.4% (17/18) 93.8 (15/16) 83.3 (10/12))~2 = 0.86 NS 
Clinical course was correctly predicted by MCA in 
24 cases, by CA15.3 in 22 cases and by CEA in 17 cases. 
Changes in MCA levels were correlated with changes in 
CA15.3 and CEA levels (MCA and CA 15.3 
r = 0.35, P = 0.03; MCA and CEA r = 0.34, P = 0.03). 
Changes in CA15.3 levels were also correlated with 
changes in CEA levels (r -- 0.34, P = 0.037). The course 
of disease was highly correlated with a change in 
marker level of MCA (r = 0.53, P =0.0004) and 
CA15.3 (r = 0.44, P = 0.0006), but less strongly with 
CEA (r = 0.32, P -- 0.044). 
Analysis of paired observations revealed that the 
association of marker level changes in MCA, CA15.3 
and CEA showed three identical patterns in only 8 of 
the 40 patients, whereas in 8 cases none correlated with 
clinical course. The association of both MCA and 
CA15.3 (concordant observations) correctly predicted 
the clinical course in 16/40 cases, CA15.3 and CEA 
correctly predicted the clinical course in 11/40 cases, 
and for MCA and CEA it was 9/40 cases. To analyse 
further the relationship between clinical change and 
markers a logistic regression analysis was used. As 
dependant variable the clinical course was divided into 
progression against non-progression and response 
against non-responsive disease. 
MCA and CA15.3 were found to contribute to the 
model significantly only in the first comparison (pro- 
gression against non-progression; P--0.037 and 
P = 0.046 respectively). Combining the two markers 
did not contribute further. In the second comparison 
(responsive against non-responsive disease), only CEA 
was a significant contributor (P = 0.026). 
Discussion 
The serum levels of MCA, CA15.3 and CEA were 
compared for their clinical usefulness in the manage- 
ment of patients with metastatic breast cancer. Of 40 
patients included in the analysis, MCA, CA15.3 and 
CEA were above the 99th percentile of the normal 
value distribution i  at least one serum sample in 75%, 
84% and 55% of the cases respectively (overall 
Z 2 = 8.5, P < 0.02; CEA versus MCA X 2 = 3.5 P = 0.1; 
CEA versus CA15.3 Z 2 = 718, P = 0.05). Relative chan- 
ges of MCA, CA15.3 and CEA levels were found to be 
correlated. When relative changes of these markers 
were correlated with disease course, the predictive 
value of a change of 25% or more in one of these 
markers proved to be high for all three markers: 94.4%, 
93.8% and 83.3%, for MCA, CA15.3 and CEA respec- 
tively. The sensitivity of these markers was poor: MCA 
60.7%, CA15.3 53.6%, CEA 35.7% with a tendency to 
higher sensitivity for both MCA and CA15.3. MCA 
and CA15.3 were highly correlated, and logistic regres- 
sion analysis demonstrated that a combination of 
MCA and CA15.3 did not further improve the predic- 
tion. Our results indicate that, if either MCA, CA15.3 
or CEA is elevated in the serum of a patient with 
metastatic breast cancer, a change of 25% or more 
accurately predicts the disease course in at least 85% of 
cases. Our results are in accord with previous reports 
suggesting that these novel serum markers, such as 
CA15.3, are superior to CEA for monitoring (Hayes et 
al. 1986; Tondini et al. 1988). 
Breast cancer often metastasizes to the skeleton and 
is the dominant feature of advanced isease in a con- 
siderable number of patients. In these cases, the disease 
course is evaluated by modestly sensitive criteria such 
as new lesions on a bone scan, the size of osteolytic 
lesions, evidence of recalcification on X-rays and blood 
chemistry results such as alkaline phosphatase and 
clinical performance. Also in our series of 76 patients, 
despite our acceptance of such criteria when concord- 
ant for evaluating disease, 17 patients, the majority of 
whom received hormonal treatment, were excluded 
from analysis because their disease course could not 
properly be evaluated. The sensitivity and predictive 
value of MCA and CA15.3 are sufficiently high to be of 
use in patients who do not have measurable and/or 
evaluable lesions. However, because of the observed 
discordances between marker pattern and objective 
disease course, these marker changes hould be con- 
sidered indicative, and cannot replace disease evalu- 
ation by conventional methods. 
Although MCA and CA15.3 have been developed 
against different epitopes of breast tumour cells, we 
have previously reported that these markers identify 
nearly the same patients (de Wit et al. 1991). Biegl- 
mayer et al. (1989) also found a similar correlation 
between these two tumour markers. On the basis of 
their results from binding tests with the antibodies used 
in the MCA and CA15.3 assays, they concluded that 
the monoclonal antibodies b-12 (MCA assay) and 115- 
D8/DF3 (CA15.3 assay) recognize coexisting epitopes 
on mucin-like antigens that belong to a number of 
glycoproteins suitable for tumour monitoring. This 
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study demonstrates that the correlation of CA15.3 and 
MCA serum levels with disease course is also nearly 
identical. Therefore, either of these newly developed 
markers can be used, and there is no advantage in 
combining the two markers. 
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